Eravacycline, a novel synthetic fluorocycline, exhibits broad-spectrum antimicrobial activity against multidrug-resistant (MDR) Gram-positive, Gram-negative, and anaerobic bacteria, making it a promising option for complicated intra-abdominal infections (cIAI). Engineered to overcome common tetracycline resistance mechanisms, eravacycline has demonstrated efficacy in vitro against MDR pathogens, including carbapenem-resistant Enterobacterales and Acinetobacter baumannii. Clinical trials (IGNITE1 and IGNITE4) established its noninferiority to carbapenems in treating cIAI, with comparable clinical cure rates but higher adverse gastrointestinal events. This retrospective study evaluates real-world eravacycline use in 13 hospitalized patients treated for complicated infections at a single center between April 2023 and August 2024. Data collected include patient demographics, infection characteristics, microbiological profiles, antibiotic regimens, and clinical outcomes. The clinical cure rate was 69.2%, with a mortality rate of 38.5%. Resistance mechanisms such as VIM-producing Klebsiella pneumoniae and Enterobacter cloacae and inadequate source control were prevalent among non-survivors. Most patients received combination therapy, primarily with beta-lactams. One suspected case of drug-induced hepatotoxicity was observed. Our findings align closely with previous case series, underscoring eravacycline's efficacy in MDR infections. However, limitations such as small sample size and retrospective design warrant further controlled studies to refine its role in complex infections beyond cIAI.